CAR-T vs. bispecifics for lymphoma: Using the evidence to sequence treatments

Curative potential at a longer follow-up, logistics and patient risk and eligibility are all important considerations when sequencing bispecific antibodies and chimeric antigen receptor T-cell therapy for advanced large B-cell lymphoma.
As part of an education program session titled “How do we calibrate cellular therapy for lymphoma in 2023?” at ASH Annual Meeting and Exposition, Manali Kamdar, MD, associate professor of medicine-hematology at University of Colorado School of Medicine, outlined an evidence-guided approach to sequencing CAR-T and bispecific antibody treatments in

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart